To date, only two clinical trials have been reported on the use of PARP inhibitors in HCC, and, unlike other cancers sites where the number of studies coupled with RT is increasing, no such studies are documented as being in progress in HCC (https://clinicaltrials.gov/, accessed on 29 July 2022) (Table 1). The gene discussed is PARP1; the disease is hepatocellular carcinoma.